Srinivas Akkaraju bought $18.8M of Scholar Rock Holding (SRRK)
Executed Oct 3 2025, disclosed Oct 8 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Oct 7 2025), the stock returned -29.9% (delay-adjusted); from the execution session (Oct 3 2025), -16.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
Srinivas Akkaraju (Director) filed 12 Form 4 reports in the trailing twelve months (12 purchases, 1 sale, 2 filed past the two-business-day deadline), most often in Alumis Inc. (ALMS). Across 11 priced purchase filings, the average 21-session return was +37.1% from execution and +27.8% from disclosure (delay-adjusted; derived). The largest single filing was $18.8M of SRRK (500,439 sh across 6 lots, as filed), executed Oct 3 2025.
Healthcare · Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular a…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→29,599 sh across 3 lots
Exec Oct 7 2025
Filed Dec 16 2025 · 9:07 PM ET † SRRKSALE Scholar Rock Holding Corporation $34.4M
1,175,713 sh across 3 lots
Exec Oct 7 2024
Filed Oct 7 2024 · 5:30 PM ET